JARROD CRUMP: Open Payments
NPI 1184240194 · MERIDIAN, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$686 in 37 payments from 15 companies in 2025. Trend: 2023 $1,004 · 2024 $577 · 2025 $686
Food & beverage: $686
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 9 | $140 |
| ABBVIE INC. | 4 | $70 |
| Corium, LLC | 4 | $65 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $57 |
| Axsome Therapeutics, Inc. | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Alkermes, Inc. | 2 | $43 |
| Tris Pharma Inc | 2 | $41 |
| Supernus Pharmaceuticals, Inc. | 2 | $38 |
| E.R. Squibb & Sons, L.L.C. | 1 | $28 |
Products named: FANAPT, VRAYLAR, Azstarys, REXULTI, CAPLYTA, Auvelity, Dyanavel XR, Qelbree.
Industry payments across ID — which companies pay providers there.
